Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized controlled trials
Authors' conclusion
MSCs have the potential to alleviate joint pain and improve joint function in patients with inflammatory arthritis.
Study context
- Population
- Patients with inflammatory arthritis: Rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS) and systemic sclerosis (SSc)
- Participants
- 2,076 patients36 RCTs
- Comparison
- Mesenchymal stem cell (MSC) transplantation in inflammatory arthritis
- Outcome
- Effectiveness and safety of MSC transplantation
Methodological detailsChinese and English databases searched from inception to July 2023, RevMan 5.4
- Chinese and English databases searched from inception to July 2023
- RevMan 5.4
Pooled result
As reported in the abstract
Visual Analog Scale (VAS) pain in OA, by MSC source
SMD (95 % CI)P value
MSC (bone marrow)
−0.95(−1.55 to −0.36)
P = 0.002MSC (umbilical cord)
−2.03(−2.99 to −1.07)
P < 0.0001MSC (adipose tissue)
−1.26(−1.99 to −0.52)
P = 0.0009Further pooled results
WOMAC scores in OA, adipose-tissue MSCs
- WOMAC pain improved
- P = 0.0001
- WOMAC physical function improved
- P = 0.001
- Total WOMAC improved
- P = 0.0003
MSC therapy in RA, AS and SSc
- Potential therapeutic effect of MSCs
Safety
- MSC therapy did not increase the incidence of adverse events
Original publication
Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized controlled trials. Semin Arthritis Rheum. Published 29 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →